Effects of gabexate mesilate, a protease inhibitor, on human sphincter of Oddi motility

Vincenzo Di Francesco, Alberto Mariani, Giampaolo Angelini, Enzo Masci, Luca Frulloni, Giorgio Talamini, Sandro Passaretti, Pieralberto Testoni, Giorgio Cavallini

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Gabexate mesilate is an antiprotease drug, which reduced the severity of pancreatitis and frequency of post-ERCP pancreatitis. In dogs gabexate inhibits sphincter of Oddi motility but no data are available in humans. The aim of this study was to verify by manometry the action of gabexate on human sphincter of Oddi motility. We enrolled 12 patients with idiopathic recurrent pancreatitis (eight males, five females, mean age 46 ± 8 years). Standard preendoscopic sphincter of Oddi manometry was done in basal conditions and during infusion of gabexate 20 mg/min: basal pressure, amplitude and frequency of phasic contractions, and motility index (amplitude per frequency) were calculated before and after gabexate injection. Statistical analysis was performed by using Wilcoxon rank test for paired data. Six patients had a manometric diagnosis of stenosis (basal pressure greater than 40 mm Hg); six had normal findings. Phasic activity was not evaluable in five patients with stenosis. Basal pressure was unaffected by drug infusion, while gabexate caused a significant reduction of phasic activity, both in terms of frequency (4.5 ± 1 vs 3.6 ± 1; P <0.05) and amplitude (157.4± 44 vs 80.0 ± 32; P <0.05) of contractions. Motility index was reduced on average by 49%. In conclusion, this pilot study confirms, in patients with acute recurrent pancreatitis, the inhibitory action of gabexate on sphincter of Oddi motility already described in dogs. This action needs to be revaluated at therapeutic dosages. On the other hand, prophylactic use of the drug should be avoided during sphincter of Oddi manometry, in order to avoid false negative results.

Original languageEnglish
Pages (from-to)741-745
Number of pages5
JournalDigestive Diseases and Sciences
Volume47
Issue number4
DOIs
Publication statusPublished - 2002

Fingerprint

Gabexate
Sphincter of Oddi
Protease Inhibitors
Pancreatitis
Manometry
Pressure
Pathologic Constriction
Pharmaceutical Preparations
Dogs
Endoscopic Retrograde Cholangiopancreatography
Nonparametric Statistics
Injections

Keywords

  • Antiprotease
  • Motility
  • Recurrent pancreatitis
  • Sphincter of Oddi

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Di Francesco, V., Mariani, A., Angelini, G., Masci, E., Frulloni, L., Talamini, G., ... Cavallini, G. (2002). Effects of gabexate mesilate, a protease inhibitor, on human sphincter of Oddi motility. Digestive Diseases and Sciences, 47(4), 741-745. https://doi.org/10.1023/A:1014775513616

Effects of gabexate mesilate, a protease inhibitor, on human sphincter of Oddi motility. / Di Francesco, Vincenzo; Mariani, Alberto; Angelini, Giampaolo; Masci, Enzo; Frulloni, Luca; Talamini, Giorgio; Passaretti, Sandro; Testoni, Pieralberto; Cavallini, Giorgio.

In: Digestive Diseases and Sciences, Vol. 47, No. 4, 2002, p. 741-745.

Research output: Contribution to journalArticle

Di Francesco, V, Mariani, A, Angelini, G, Masci, E, Frulloni, L, Talamini, G, Passaretti, S, Testoni, P & Cavallini, G 2002, 'Effects of gabexate mesilate, a protease inhibitor, on human sphincter of Oddi motility', Digestive Diseases and Sciences, vol. 47, no. 4, pp. 741-745. https://doi.org/10.1023/A:1014775513616
Di Francesco, Vincenzo ; Mariani, Alberto ; Angelini, Giampaolo ; Masci, Enzo ; Frulloni, Luca ; Talamini, Giorgio ; Passaretti, Sandro ; Testoni, Pieralberto ; Cavallini, Giorgio. / Effects of gabexate mesilate, a protease inhibitor, on human sphincter of Oddi motility. In: Digestive Diseases and Sciences. 2002 ; Vol. 47, No. 4. pp. 741-745.
@article{50419af75d64441295d0af85f1227ba2,
title = "Effects of gabexate mesilate, a protease inhibitor, on human sphincter of Oddi motility",
abstract = "Gabexate mesilate is an antiprotease drug, which reduced the severity of pancreatitis and frequency of post-ERCP pancreatitis. In dogs gabexate inhibits sphincter of Oddi motility but no data are available in humans. The aim of this study was to verify by manometry the action of gabexate on human sphincter of Oddi motility. We enrolled 12 patients with idiopathic recurrent pancreatitis (eight males, five females, mean age 46 ± 8 years). Standard preendoscopic sphincter of Oddi manometry was done in basal conditions and during infusion of gabexate 20 mg/min: basal pressure, amplitude and frequency of phasic contractions, and motility index (amplitude per frequency) were calculated before and after gabexate injection. Statistical analysis was performed by using Wilcoxon rank test for paired data. Six patients had a manometric diagnosis of stenosis (basal pressure greater than 40 mm Hg); six had normal findings. Phasic activity was not evaluable in five patients with stenosis. Basal pressure was unaffected by drug infusion, while gabexate caused a significant reduction of phasic activity, both in terms of frequency (4.5 ± 1 vs 3.6 ± 1; P <0.05) and amplitude (157.4± 44 vs 80.0 ± 32; P <0.05) of contractions. Motility index was reduced on average by 49{\%}. In conclusion, this pilot study confirms, in patients with acute recurrent pancreatitis, the inhibitory action of gabexate on sphincter of Oddi motility already described in dogs. This action needs to be revaluated at therapeutic dosages. On the other hand, prophylactic use of the drug should be avoided during sphincter of Oddi manometry, in order to avoid false negative results.",
keywords = "Antiprotease, Motility, Recurrent pancreatitis, Sphincter of Oddi",
author = "{Di Francesco}, Vincenzo and Alberto Mariani and Giampaolo Angelini and Enzo Masci and Luca Frulloni and Giorgio Talamini and Sandro Passaretti and Pieralberto Testoni and Giorgio Cavallini",
year = "2002",
doi = "10.1023/A:1014775513616",
language = "English",
volume = "47",
pages = "741--745",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Effects of gabexate mesilate, a protease inhibitor, on human sphincter of Oddi motility

AU - Di Francesco, Vincenzo

AU - Mariani, Alberto

AU - Angelini, Giampaolo

AU - Masci, Enzo

AU - Frulloni, Luca

AU - Talamini, Giorgio

AU - Passaretti, Sandro

AU - Testoni, Pieralberto

AU - Cavallini, Giorgio

PY - 2002

Y1 - 2002

N2 - Gabexate mesilate is an antiprotease drug, which reduced the severity of pancreatitis and frequency of post-ERCP pancreatitis. In dogs gabexate inhibits sphincter of Oddi motility but no data are available in humans. The aim of this study was to verify by manometry the action of gabexate on human sphincter of Oddi motility. We enrolled 12 patients with idiopathic recurrent pancreatitis (eight males, five females, mean age 46 ± 8 years). Standard preendoscopic sphincter of Oddi manometry was done in basal conditions and during infusion of gabexate 20 mg/min: basal pressure, amplitude and frequency of phasic contractions, and motility index (amplitude per frequency) were calculated before and after gabexate injection. Statistical analysis was performed by using Wilcoxon rank test for paired data. Six patients had a manometric diagnosis of stenosis (basal pressure greater than 40 mm Hg); six had normal findings. Phasic activity was not evaluable in five patients with stenosis. Basal pressure was unaffected by drug infusion, while gabexate caused a significant reduction of phasic activity, both in terms of frequency (4.5 ± 1 vs 3.6 ± 1; P <0.05) and amplitude (157.4± 44 vs 80.0 ± 32; P <0.05) of contractions. Motility index was reduced on average by 49%. In conclusion, this pilot study confirms, in patients with acute recurrent pancreatitis, the inhibitory action of gabexate on sphincter of Oddi motility already described in dogs. This action needs to be revaluated at therapeutic dosages. On the other hand, prophylactic use of the drug should be avoided during sphincter of Oddi manometry, in order to avoid false negative results.

AB - Gabexate mesilate is an antiprotease drug, which reduced the severity of pancreatitis and frequency of post-ERCP pancreatitis. In dogs gabexate inhibits sphincter of Oddi motility but no data are available in humans. The aim of this study was to verify by manometry the action of gabexate on human sphincter of Oddi motility. We enrolled 12 patients with idiopathic recurrent pancreatitis (eight males, five females, mean age 46 ± 8 years). Standard preendoscopic sphincter of Oddi manometry was done in basal conditions and during infusion of gabexate 20 mg/min: basal pressure, amplitude and frequency of phasic contractions, and motility index (amplitude per frequency) were calculated before and after gabexate injection. Statistical analysis was performed by using Wilcoxon rank test for paired data. Six patients had a manometric diagnosis of stenosis (basal pressure greater than 40 mm Hg); six had normal findings. Phasic activity was not evaluable in five patients with stenosis. Basal pressure was unaffected by drug infusion, while gabexate caused a significant reduction of phasic activity, both in terms of frequency (4.5 ± 1 vs 3.6 ± 1; P <0.05) and amplitude (157.4± 44 vs 80.0 ± 32; P <0.05) of contractions. Motility index was reduced on average by 49%. In conclusion, this pilot study confirms, in patients with acute recurrent pancreatitis, the inhibitory action of gabexate on sphincter of Oddi motility already described in dogs. This action needs to be revaluated at therapeutic dosages. On the other hand, prophylactic use of the drug should be avoided during sphincter of Oddi manometry, in order to avoid false negative results.

KW - Antiprotease

KW - Motility

KW - Recurrent pancreatitis

KW - Sphincter of Oddi

UR - http://www.scopus.com/inward/record.url?scp=0036221245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036221245&partnerID=8YFLogxK

U2 - 10.1023/A:1014775513616

DO - 10.1023/A:1014775513616

M3 - Article

VL - 47

SP - 741

EP - 745

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 4

ER -